Vanguard Global Advisers’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
Vanguard Global Advisers's CCCC Position: Q3 2026 in Review
Vanguard Global Advisers increased its C4 Therapeutics (CCCC) stake by 27% in Q3 2026, buying an estimated $33.8K and bringing the position to 42,890 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #2613.
Vanguard Global Advisers first reported a position in CCCC in Q1 2026 and has held it in 3 quarters since. The position peaked at $158K in Q2 2026. 151 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Vanguard Global Advisers held 42,890 shares of C4 Therapeutics worth $143K as of Q3 2026.
- Vanguard Global Advisers bought 9,058 C4 Therapeutics shares in Q3 2026, an estimated $33.8K.
- C4 Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2613 holding.
- Vanguard Global Advisers first reported a position in C4 Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's C4 Therapeutics position peaked at $158K in Q2 2026.
- 151 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.